Most participants were people with coronary artery disease who had enrolled in trials of statin monotherapy primarily evaluating cardiovascular endpoints.
Scientific Publications
Occupation and cutaneous melanoma: A 45-year historical cohort study of 14·9 million people in five Nordic countries
Since few prospective population?based studies have estimated the occupational variation in cutaneous melanoma (CM) risk over time, researchers sought to determine occupational variation in CM risk.
Association of anti-programmed cell death 1 antibody treatment with risk of recurrence of toxic effects after immune-related adverse events of ipilimumab in patients with metastatic melanoma
In this cohort study involving 56 patients with metastatic melanoma, researchers sought to assess the risk of a recurrence of immune toxic effects correlated with anti-programmed cell death 1 antibody (anti–PD-1) therapy after discontinuation of ipilimumab monotherapy due to severe adverse events (AEs).
Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma
Given that significantly longer relapse-free survival with 12 months of adjuvant dabrafenib plus trametinib vs placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations has been reported in the earlier reported primary analysis of this phase 3 trial, researchers undertook this investigation to corroborate the stability of the relapse-free survival benefit.